YiChang HEC ChangJiang Pharmaceutical Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
YiChang HEC ChangJiang Pharmaceutical heeft een totaal eigen vermogen van CN¥8.7B en een totale schuld van CN¥2.1B, wat de schuld-eigenvermogensverhouding op 23.9% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥12.5B en CN¥3.8B. De EBIT YiChang HEC ChangJiang Pharmaceutical is CN¥2.1B waardoor de rentedekking 30.4 is. Het heeft contanten en kortetermijnbeleggingen van CN¥1.5B.
Belangrijke informatie
23.9%
Verhouding schuld/eigen vermogen
CN¥2.07b
Schuld
Rente dekkingsratio | 30.4x |
Contant | CN¥1.52b |
Aandelen | CN¥8.67b |
Totaal verplichtingen | CN¥3.83b |
Totaal activa | CN¥12.49b |
Recente financiële gezondheidsupdates
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt
Sep 25Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?
Nov 25Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?
Mar 23Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden
Apr 13Recent updates
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Strong Profits May Be Masking Some Underlying Issues
Oct 07Should You Be Adding YiChang HEC ChangJiang Pharmaceutical (HKG:1558) To Your Watchlist Today?
Sep 19YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Popularity With Investors Under Threat As Stock Sinks 26%
May 29Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?
Apr 23YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce
Mar 01Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%
Mar 01YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't
Jan 03YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt
Sep 25Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?
Nov 25Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?
Mar 23Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?
Oct 29Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden
Apr 13YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially
Mar 23YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.
Mar 13YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?
Feb 20Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?
Feb 02YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Dec 26Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend
Dec 13What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Nov 30Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( CN¥5.5B ) 1558 } overtreffen de korte termijn passiva ( CN¥2.5B ).
Langlopende schulden: De kortetermijnactiva 1558 ( CN¥5.5B ) overtreffen de langetermijnschulden ( CN¥1.3B ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 6.3% ) 1558 wordt als voldoende beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van 1558 is de afgelopen 5 jaar gedaald van 74.6% naar 23.9%.
Schuldendekking: De schuld van 1558 wordt goed gedekt door de operationele kasstroom ( 21.9% ).
Rentedekking: De rentebetalingen op de schuld van 1558 worden goed gedekt door EBIT ( 30.4 x dekking).